微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 53.13% | 17.2% | 4.25% | 71/157 | 50.55% | 泽璟制药 | 94.64% | 行业排名> |
| 2025-12-31 | 50.97% | 8.12% | 1.41% | 71/157 | 50.61% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 50.26% | 10.34% | 7.94% | 73/157 | -2.2% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 46.56% | 4.29% | 2.7% | 84/157 | 14.83% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 45.34% | 3.52% | -3.83% | 81/157 | 31.96% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 47.14% | 5.06% | 3.5% | 86/157 | 51.88% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 45.55% | 3.96% | 2.02% | 86/157 | 22.51% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 44.64% | 0.1% | 1.94% | 89/157 | 33.12% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 43.79% | -7.69% | -2.39% | 88/157 | 51.76% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 44.87% | 4.48% | 2.41% | 93/157 | 51.61% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 43.81% | 3.98% | -1.76% | 95/157 | 32.47% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 44.6% | 11.71% | -6% | 93/157 | 38.42% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 47.44% | 24.67% | 10.48% | 83/157 | 52.97% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 42.94% | 4.85% | 1.92% | 97/157 | 53.83% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 42.13% | 2.18% | 5.54% | 92/157 | 5.64% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 39.92% | 1.47% | 4.91% | 100/157 | 20.99% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 38.05% | -1% | -7.08% | 99/157 | 54.39% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 40.95% | -16% | -0.68% | 98/157 | 55.2% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 41.23% | -19.91% | 4.8% | 86/157 | 46.77% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 39.35% | -19.08% | 2.37% | 102/157 | 47.23% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 38.44% | -15.68% | -21.16% | 87/157 | 54.13% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 48.76% | -17.85% | -5.31% | 81/157 | -148.64% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 51.49% | -13.55% | 5.89% | 65/157 | 56.43% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 48.63% | -19% | 6.67% | 73/157 | 54.17% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 45.59% | -23.07% | -23.19% | 70/157 | 55.17% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 59.35% | 3.56% | -0.34% | 61/157 | -1242.15% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-09-30 | 59.56% | 4.37% | -0.79% | 48/157 | 55.23% | 微芯生物 | 95.81% | 行业排名> |
| 2019-06-30 | 60.03% | 8.75% | 1.3% | 46/157 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-03-31 | 59.26% | 16.77% | 3.4% | 40/157 | 51.07% | 微芯生物 | 96.11% | 行业排名> |
| 2018-12-31 | 57.31% | 5.09% | 0.44% | 61/157 | -211.97% | 微芯生物 | 95.5% | 行业排名> |
| 2018-09-30 | 57.06% | 4.41% | 3.37% | 48/157 | 54.14% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 55.2% | 4.76% | 8.78% | 51/157 | 53.53% | 贝达药业 | 95.47% | 行业排名> |
| 2018-03-31 | 50.75% | -1.15% | -6.95% | 55/157 | 54.16% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 54.54% | 15.72% | -0.21% | 55/157 | 52.55% | 贝达药业 | 95.54% | 行业排名> |
| 2017-09-30 | 54.65% | 30.56% | 3.72% | 39/157 | 49.09% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 52.69% | 23.62% | 2.65% | 40/157 | 47.91% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 51.33% | 39.24% | 8.93% | 36/157 | 46.94% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 47.13% | 24.19% | 12.58% | 53/157 | 48.46% | 退市金泰 | 95.93% | 行业排名> |
| 2016-09-30 | 41.86% | 29.53% | -1.8% | 43/157 | 46.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 42.63% | 32.12% | 15.62% | 45/157 | 46.26% | 贝达药业 | 95.89% | 行业排名> |
| 2016-03-31 | 36.87% | 11.4% | -2.85% | 47/157 | 43.86% | 微芯生物 | 97.46% | 行业排名> |